

Published in final edited form as:


J Org Chem. 2008 September 19; 73(18): 7017–7027. doi:10.1021/jo8015314.

Synthesis of Neoglycoconjugates by the Desulfurative Rearrangement of Allylic Disulfides

David Crich* and Fan Yang

Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202.

Abstract



Two series of neoglycosyl donors are prepared based on connection of the allylic disulfide motif to the anomeric center via either a simple *O*-glycosyl linkage or *N*-glycosyl amide unit. Conjugation of both sets of donors to cysteine in peptides is demonstrated through classical disulfide exchange followed by the phosphine-mediated desulfurative allylic rearrangement resulting in neoglycopeptides characterized by a simple thioether spacer. The conjugation reaction functions in the absence of protecting groups on both the neoglycosyl donor and peptide in aqueous media at room temperature.

Introduction

We have introduced the desulfurative rearrangement of allylic disulfides (Scheme 1) as a facile means of electrophile-free, permanent functionalization of thiols suitable for the modification of cysteine and other thiols.¹ Herein we report on the extension of this chemistry to the ligation of carbohydrates to cysteine in peptides and proteins.

The ability to prepare glycosylated peptides and proteins is critical to the pursuit and advancement of glycomics and glycoscience.² The generation of native linkages between oligosaccharides and peptides typically requires the assembly of preglycosylated peptide building blocks into larger peptides, as exemplified by recent groundbreaking syntheses employing the method of native chemical ligation,³ whereas the synthesis of neoglycoconjugates in principle allows the conjugation of oligosaccharides to fully assembled peptides and even proteins.⁴ Among the many elegant methods devised,^{1b,5} the disulfide ligation, as applied to peptides and proteins by the Boons and Davis groups,⁶ stands out for the mildness of conditions and broad functional group tolerance. The impermanence of the disulfide ligation, due to the ease of reduction and/or scrambling processes, has promoted the search for methods to convert the disulfide to a simple thioether which have so far been marred by a loss of stereochemical integrity of the cysteine residue involved in the linkage.⁷ The application of the desulfurative allylic rearrangement that we describe here combines the broad functional group compatibility of the disulfide linkage with the formation of permanent thioether type bond, and the maintenance of stereochemical integrity of the peptide chain.

Results and Discussion

In our approach to neoglycoconjugate synthesis we envisaged the use of a short spacer, resulting from the ligation reaction itself, to link the carbohydrate to the peptide. We preferred to accommodate the inherent requirement of the desulfurative allylic disulfide rearrangement for an allylic sulfide through the use of an appropriate tether, rather than attempt incorporation of this functionality into the saccharide itself to limit the number of chemical manipulations prior to the ligation reaction. To this end, in a first generation approach, a series of glycosyl bromides were coupled in β -selective reactions to cis-butene-1,4-diol (Scheme 2). Subsequent functionalization of the residual alcohol as a thionocarbonate ester was followed by heating in toluene at reflux to provoke [3,3]-sigmatropic rearrangement⁸ and the formation of allylic thiolcarbonates as mixtures of stereoisomers at the newly generated stereogenic center. Selective hydrazinolysis of the thiolcarbonate gave the corresponding allylic thiols which were not isolated but immediately converted to the benzothiazolyl disulfides in high yield (Scheme 2).

Exactly analogous chemistry with a sialosyl chloride gave an α -sialyl glycoside carrying the allylic disulfide moiety at the anomeric position (Scheme 3).

A more efficient second generation protocol involved application of the allylic thionocarbonate rearrangement to the mono-(*tert*-butyldimethylsilyl) ether of cis-butene-1,4-diol, and desilylation followed by glycosylation by the trichloroacetimidate method⁹ to intercept the first generation method at the stage of the glycosylated thiolcarbonates **4a–c** (Scheme 4).¹⁰

The ideal approach (third generation) involved direct glycosylation of the known³ hydroxylated allylic disulfide **14**, accessible from **12** by cleavage of the thiolcarbonate and sulfenylation in the usual manner, with glycosyl donors **13a–c**. Unfortunately, while this approach was successful (Scheme 5), it provided the desired products in only moderate yield and resulted in complications in a subsequent step (*vide infra*).

With four protected neoglycosyl donors in hand a series of couplings were attempted to model cysteine-containing peptides. These reactions were conducted at room temperature by mixing the peptide and the neoglycosyl donor in acetonitrile/methanol (1:1) as solvent and, after the sulfenyl transfer stage was complete, adding triphenylphosphine to provoke the key rearrangement and render the ligation complete. Initial reactions were conducted with protected peptides, before compatibility with free glutathione was employed in an aqueous medium. In all cases the ligation proceeded efficiently, with the products being obtained in a highly trans-selective manner with respect to the linker (Table 1).

Deprotection of the neoglycoconjugate donors encountered several problems owing to the sensitivity of both disulfides¹¹ and allylic thiols^{8c} to basic conditions. Thus, Zemplen type cleavage of disulfides **5a–c** and **10** gave complex reaction mixtures from which only low yields of the desired products could be isolated. Optimal conditions were eventually found involving a mild saponification at the level of the thiolcarbonates **4b, c** and **9**, with concomitant removal of the thiolcarbonate and direct sulfenylation of the released thiol without isolation (Scheme 6). The optimum synthesis of the free neoglycosyl donors is therefore the combination of the second generation approach to the protected donor (Scheme 3), followed by saponification and sulfenylation (Scheme 6).

Conjugation of the fully deprotected neoglycosyl donors **25** and **26** to the model peptide glutathione was achieved without issue in pH 8.0 phosphate buffer by simply mixing to achieve sulfenyl transfer and adding triphenylphosphine to bring about the sigmatropic rearrangement (Table 2). Interestingly, the yields in the protecting group free reactions conducted in phosphate buffer (Table 2) are routinely higher than those conducted with protected neoglycosyl donors

in organic solvent mixtures (Table 1), which we attribute to the established facilitation of the desulfurative allylic disulfide rearrangement in polar solvents^{1c} at the expense of the background phosphine-mediated disulfide cleavage reaction.

A second allylic disulfide linker was prepared as set out in Scheme 7 with a view to mimicking the N-glycosyl amides linkage. Thus, aldol **31** was subjected to the thio-Mitsunobu reaction¹² to give the thioacetate **32**. Saponification and sulfenylation then afforded disulfide **33** which was converted to the free acid **34** by exposure to trifluoroacetic acid.

Standard peptide coupling reactions then enabled acid **34** to be affixed to glycosylamines in the complete absence of protecting groups (Scheme 8). Although the yields for this coupling process are only moderate at the present time, it possesses the very obvious advantages of convergency and the direct provision of neoglycosyl donors ready for conjugation without the need for further protecting group manipulation.

Neoglycoconjugate synthesis with donors **36** was conducted in aqueous buffer and proceeded in excellent yield (Table 3).

Experimental Section

General

All reagents were purchased from commercial sources and used as received, unless otherwise indicated, and all reaction solvents were anhydrous. All reactions were conducted under an atmosphere of dry nitrogen. Organic extracts were dried over sodium sulfate, and concentrated under aspirator vacuum at room temperature.

General Procedure for the Reaction of Glycosyl Bromides with cis-But-2-ene-1,4-diol (**2a-c**, **7**).¹³

cis-But-2-ene-1,4-diol (10 mL, 120 mmol), Ag₂CO₃ (750 mg, 2.7 mmol), CaSO₄ (2 g) and an iodine crystal were stirred with the exclusion of moisture and light for 0.5 h at room temperature before a glycosyl bromide (**1a-c**) (1.9 mmol) or the sialyl chloride (**6**) was added. The reaction mixture was stirred at room temperature for 24 h, then diluted with dichloromethane (25 mL), filtered through Celite and the filtrate washed with water. The solvent was removed by evaporation and the mixture was purified by chromatography over silica gel to afford the glycosides (**2a-c** and **7**).

(Z)-4-Hydroxybut-2-enyl Tetra-O-acetyl-β-D-glucopyranoside (2a)—White solid, eluted from silica gel with hexane/ethyl acetate (2:1) in 84% yield. M.p. 97 °C; [α]_D²⁵ −15.3° (c, 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.82 (m, 1H), 5.60 (m, 1H), 5.18 (t, J = 9.5 Hz, 1H), 5.06 (t, J = 9.5 Hz, 1H), 4.97 (dd, J = 8.0, J = 9.5 Hz, 1H), 4.55 (d, J = 8.0 Hz, 1H), 4.34 (dd, J = 6.0, J = 12.5 Hz, 1H), 4.24 (m, 2H), 4.17 (d, J = 6.5 Hz, 2H), 4.14 (dd, J = 2.0, J = 10.0 Hz, 1H), 3.69 (m, 1H), 2.08 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ: 170.8, 170.3, 169.5, 133.4, 126.7, 99.3, 72.8, 71.8, 71.2, 68.4, 64.3, 62.0, 58.5, 20.8, 20.7, 20.6; Anal. Calcd for C₁₈H₂₆O₁₁ C, 51.33; H, 6.28; N, 2.49; Found, C, 51.22; H, 6.01; N, 2.44.

(Z)-4-Hydroxybut-2-enyl Tetra-O-acetyl-β-D-galactopyranoside (2b)—Syrup, eluted from silica gel with hexane/ethyl acetate (2:1) in 83% yield. [α]_D¹⁵ −9.6° (c, 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.75 (m, 1H), 5.52 (m, 1H), 5.30 (d, J = 3.5 Hz, 1H), 5.11 (dd, J = 8.0, J = 10.5 Hz, 1H), 4.93 (dd, J = 3.5, J = 10.5 Hz, 1H), 4.45 (d, J = 8.0 Hz, 1H), 4.28 (dd, J = 7.5, J = 12.5 Hz, 1H), 4.20 (dd, J = 7.5, J = 12.5 Hz, 1H), 4.11-4.02 (m, 1H), 3.86 (t, J = 6.5 Hz, 1H), 2.07 (s, 3H), 1.98 (s, 6H), 1.89 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ: 170.5, 170.3, 170.1, 169.6, 133.5, 126.4, 99.6, 70.9, 70.6, 68.7, 67.1, 64.2, 61.4,

58.3, 20.7, 20.64, 20.5; ESIHRMS Calcd. for C₁₈H₂₆O₁₁Na [M+Na]⁺ 441.1368, found 441.1361.

(Z)-4-Hydroxybut-2-enyl Hepta-O-acetyl-β-D-cellobioside (2c)—White solid, eluted from silica gel with hexane/ethyl acetate (1:3) in 81% yield; M.p. 171 °C; [α]_D¹⁵ -21.8° (c, 1.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.83 (m, 1H), 5.60 (m, 1H), 5.15 (m, 2H), 5.05 (t, *J* = 9.5 Hz, 1H), 5.90 (m, 2H), 4.55-4.50 (m, 3H), 4.35 (dd, *J* = 4.5, *J* = 12.5 Hz, 1H), 4.31 (dd, *J* = 6.0, *J* = 13.0 Hz, 1H), 4.23 (dd, *J* = 7.5, *J* = 12.5 Hz, 1H), 4.17 (d, *J* = 6.5 Hz, 2H), 4.09-4.03 (m, 2H), 3.76 (t, *J* = 9.5 Hz, 1H), 3.64 (m, 1H), 3.59 (m, 1H), 2.13 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 2.003 (s, 3H), 1.998 (s, 3H), 1.97 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ: 170.6, 170.4, 170.2, 169.8, 169.7, 169.3, 169.1, 133.5, 126.6, 100.7, 99.1, 76.4, 72.9, 72.7, 72.4, 71.9, 71.6, 71.5, 67.7, 64.3, 61.8, 61.5, 58.4, 20.9, 20.70, 20.66, 20.5; ESIHRMS Calcd. for C₃₀H₄₂O₁₉Na [M+Na]⁺ 729.2218, found 729.2191.

(Z)-4-Hydroxybut-2-enyl (Methyl 4,7,8,9-tetra-O-acetyl-5-acetylamino-3,5-dideoxy-β-glycero-α-D-galacto-non-2-ulopyranosylonate) (7)—White solid, eluted from silica gel with ethyl acetate in 58% yield. M.p. 130.1 °C; [α]_D²⁴ -11.2° (c, 1.2, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.74 (m, 1H), 5.57 (m, 1H), 5.44 (m, 1H), 5.30 (dd, *J* = 0.5, *J* = 8.5 Hz, 1H), 5.25 (dd, *J* = 0.5, *J* = 9.5 Hz, 1H), 4.83 (m, 1H), 4.34 (m, 1H), 4.20 (m, 1H), 4.12 (dd, *J* = 6.5, *J* = 13.5 Hz, 1H), 4.05 (m, 4H), 3.78 (s, 3H), 2.59 (dd, *J* = 4.5, *J* = 12.5 Hz, 1H), 2.16 (s, 3H), 2.14 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.87 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ: 171.04, 170.96, 170.5, 170.3, 168.4 (C-1, *J*_{C-1,H-3ax} = 5.0 Hz), 131.8, 127.5, 98.4, 72.4, 69.0, 68.4, 67.3, 62.7, 61.1, 58.3, 52.8, 49.4, 38.1, 23.2, 21.2, 20.9, 20.8; Anal. Calcd for C₂₄H₃₅NO₁₄ C, 51.33; H, 6.28; N, 2.49; Found, C, 51.22; H, 6.01; N, 2.44.

General Procedure for the Reaction of Hydroxybutenyl Glycosides with Phenyl Thionochloroformate (3a-c, 8)

A solution of phenyl chlorothionocarbonate (158 μL, 1.14 mmol) in dichloromethane (3 mL) was added to a solution of the alcohols 2a-c (0.38 mmol), pyridine (184 μL, 2.28 mmol) and DMAP (6 mg) in dichloromethane (2 mL), and the resulting yellow solution was stirred at room temperature for 5 h. The reaction mixture was poured into H₂O (10 mL), and extracted with dichloromethane (3×10 mL). The combined organic phases were dried, filtered, evaporated, and purified by chromatography over silica gel.

(Z)-4-(Phenyloxythionocarbonyloxy)-2-butenyl Tetra-O-acetyl-β-D-glucopyranoside (3a)—Yellow syrup, eluted from silica gel with hexane/ethyl acetate (1:1) in 96% yield. [α]_D²¹ -9.0° (c, 1.2, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 7.42 (t, *J* = 8.0 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.09 (t, *J* = 8.0 Hz, 2H), 5.87 (m, 1H), 5.80 (m, 1H), 5.19 (t, *J* = 9.5 Hz, 1H), 5.09 (m, 3H), 5.00 (dd, *J* = 8.0, *J* = 9.5 Hz, 1H), 4.56 (d, *J* = 8.0 Hz, 1H), 4.38 (dq, *J* = 5.5, *J* = 13.5 Hz, 2H), 4.25 (dd, *J* = 4.5, *J* = 12.0 Hz, 1H), 4.15 (dd, *J* = 2.0, *J* = 12.0 Hz, 1H), 3.69 (m, 1H), 2.07 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ: 194.9, 170.7, 170.3, 169.41, 169.39, 153.4, 130.6, 129.6, 126.7, 126.1, 121.9, 99.5, 72.8, 71.9, 71.2, 69.2, 68.3, 64.6, 61.9, 20.79, 20.75, 20.6; ESIHRMS Calcd. for C₂₅H₃₀O₁₂SNa [M+Na]⁺ 577.1356, found 577.1338.

(Z)-4-(Phenyloxythionocarbonyloxy)-2-butenyl Tetra-O-acetyl-β-D-galactopyranoside (3b)—Yellow syrup, eluted from silica gel with hexane/ethyl acetate (1:1) in 90% yield. [α]_D¹⁵ -3.5° (c, 1.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 7.38 (m, 2H), 7.26 (dt, *J* = 1.0, *J* = 7.5 Hz, 1H), 7.07 (m, 2H), 5.81 (m, 2H), 5.34 (dd, *J* = 0.5, *J* = 3.5 Hz, 1H), 5.19 (dd, *J* = 8.0, *J* = 10.5 Hz, 1H), 5.07 (m, 2H), 4.97 (dd, *J* = 3.5, *J* = 10.5 Hz, 1H), 4.50 (d, *J* = 8.0 Hz, 1H), 4.39 (dd, *J* = 5.5, *J* = 12.5 Hz, 1H), 4.32 (dd, *J* = 6.5, *J* = 12.5 Hz, 1H), 4.12 (d, *J* = 7.0 Hz, 1H), 3.88 (dt, *J* = 1.5, *J* = 6.5 Hz, 1H), 2.10 (s, 3H), 2.02 (s, 3H), 1.98 (s,

3H), 1.93 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ : 194.9, 170.3, 170.2, 170.1, 169.4, 153.4, 130.7, 129.6, 126.7, 125.9, 121.9, 100.0, 70.9, 70.8, 69.2, 68.7, 67.1, 64.6, 61.3, 20.8, 20.7, 20.6; ESIHRMS Calcd. for $\text{C}_{25}\text{H}_{30}\text{O}_{12}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 577.1356, found 577.1344.

(Z)-4-(Phenyloxythionocarbonyloxy)-2-butenyl Hepta-O-acetyl- β -D-cellobioside (3c)—Yellow syrup, eluted from silica gel with hexane/ethyl acetate (1:1) in 96% yield, $[\alpha]_{\text{D}}^{15} -18.1^\circ$ (c, 1.2, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ : 7.42 (t, $J = 8.0$ Hz, 2H), 7.30 (m, 1H), 7.09 (m, 2H), 5.87 (m, 1H), 5.79 (m, 1H), 5.19-5.03 (m, 5H), 4.91 (m, 2H), 4.54-4.48 (m, 3H), 4.40-4.31 (m, 3H), 3.78 (t, $J = 9.5$ Hz, 1H), 3.64 (m, 1H), 3.58 (m, 1H), 2.13 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ : 195.0, 170.5, 170.33, 170.26, 169.8, 169.7, 169.3, 169.1, 153.4, 130.6, 129.6, 126.7, 126.1, 121.9, 100.8, 99.3, 76.4, 72.9, 72.8, 72.5, 72.0, 71.6, 71.4, 69.2, 67.8, 64.6, 61.8, 61.5, 21.0, 20.8, 20.7, 20.6; ESIHRMS Calcd. for $\text{C}_{37}\text{H}_{46}\text{O}_{20}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 865.2201, found 865.2173.

(Z)-4-(Phenyloxythionocarbonyloxy)-2-butenyl (Methyl 4,7,8,9-tetra-O-acetyl-5-acetyl-amino-3,5-dideoxy-D-glycero- α -D-galacto-non-2-ulopyranosylonate) (8)—Yellow syrup, eluted from silica gel with dichloromethane/methanol (10:1) in 99% yield. $[\alpha]_{\text{D}}^{24} -12.6^\circ$ (c, 1.2, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ : 7.41 (d, $J = 8.0$ Hz, 2H), 7.29 (d, $J = 8.0$ Hz, 1H), 7.09 (d, $J = 8.0$ Hz, 2H), 5.79 (m, 1H), 5.43 (m, 1H), 5.32 (dd, $J = 2.0$, $J = 8.5$ Hz, 1H), 5.24 (d, $J = 9.0$ Hz, 1H), 5.14 (dd, $J = 1.5$, $J = 6.5$ Hz, 2H), 4.85 (m, 1H), 4.41 (dd, $J = 5.0$, $J = 13.5$ Hz, 1H), 4.29 (dd, $J = 2.5$, $J = 12.5$ Hz, 1H), 4.06 (m, 4H), 3.79 (s, 3H), 2.60 (dd, $J = 4.5$, $J = 13.0$ Hz, 2H), 2.16 (s, 3H), 2.12 (s, 3H), 2.023 (s, 3H), 2.017 (s, 3H), 1.87 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ : 194.9, 171.0, 170.7, 170.24, 170.18, 170.1, 168.2, 153.5, 130.3, 129.6, 126.6, 125.5, 121.9, 98.5, 72.5, 69.8, 69.0, 68.3, 67.2, 61.0, 52.9, 49.4, 38.0, 23.2, 21.2, 20.9, 20.8; ESIHRMS Calcd. for $\text{C}_{31}\text{H}_{39}\text{NO}_{15}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 720.1933, found 720.1928.

General Procedure for the [3,3]-Sigmatropic Rearrangement Reaction of Allylic Thionocarbonates (4a–c, 9)

A solution of **3a–c** or **8** in toluene was heated at reflux for 8h–12h. Evaporation of the solvent afforded **4a–c** or **9** as yellow syrups in quantitative yield.

2-(Phenyloxythionocarbonyloxy)-3-butenyl Tetra-O-acetyl- β -D-glucopyranoside (4a)—An approximately 1:1 mixture of diastereomers with ^1H NMR (500 MHz, CDCl_3) δ : 7.38 (m, 2 \times 2H), 7.24 (t, $J = 7.5$ Hz, 2 \times 1H), 7.15 (m, 2 \times 2H), 5.90 (m, 2 \times 1H), 5.39 (dd, $J = 3.5$, $J = 17.0$ Hz, 2 \times 1H), 5.22 (m, 2 \times 2H), 5.08 (dt, $J = 3.5$, $J = 10.0$ Hz, 2 \times 1H), 5.02 (dt, $J = 2.0$, $J = 8.0$ Hz, 2 \times 1H), 4.58 (d, $J = 8.0$ Hz, 1H), 4.56 (d, $J = 8.0$ Hz, 1H), 4.16 (m, 2 \times 4H), 3.79 (m, 2 \times 1H), 3.70 (m, 2 \times 1H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.018 (s, 3H), 2.017 (s, 3H), 2.003 (s, 3H), 2.000 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ : 170.7, 170.3, 169.4, 169.3, 169.0, 168.96, 168.92, 168.31, 168.29, 151.1, 133.6, 129.6, 126.3, 121.3, 119.0, 118.9, 101.3, 100.5, 72.7, 72.6, 71.9, 71.8, 71.04, 71.98, 70.5, 68.4, 68.3, 61.9, 61.8, 48.5, 47.9, 20.8, 20.6; ESIHRMS Calcd. for $\text{C}_{25}\text{H}_{30}\text{O}_{12}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 577.1356, found 577.1339.

2-(Phenyloxythionocarbonyloxy)-3-butenyl Tetra-O-acetyl- β -D-galactopyranoside (4b)—An approximately 1:1 mixture of diastereomers with ^1H NMR (500 MHz, CDCl_3) δ : 7.38 (m, 2 \times 2H), 7.25 (t, $J = 7.5$ Hz, 2 \times 2H), 7.15 (m, 2 \times 2H), 5.92 (m, 2 \times 1H), 5.39 (m, 2 \times 2H), 5.24 (m, 2 \times 2H), 5.02 (m, 2 \times 1H), 4.53 (d, $J = 8.5$ Hz, 1H), 4.51 (d, $J = 8.5$ Hz, 1H), 4.21-4.10 (m, 2 \times 4H), 3.91 (m, 2 \times 1H), 3.79 (m, 2 \times 1H), 2.513 (s, 3H), 2.148 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ : 170.4, 170.3, 170.2, 169.5, 169.4, 168.9, 151.1, 133.8, 133.4, 129.6, 126.3, 121.3, 118.9, 118.8,

101.8, 101.1, 71.7, 70.83, 70.76, 70.5, 68.6, 68.5, 67.0, 61.3, 48.6, 48.0, 20.88, 20.83, 20.7, 20.6; ESIHRMS Calcd. for $C_{25}H_{30}O_{12}SNa$ $[M+Na]^+$ 577.1356, found 577.1331.

2-(Phenyloxycarbonylthioxy)-3-butenyl Hepta-O-acetyl- β -D-cellobioside (4c)—

An approximately 1:1 mixture of diastereomers with 1H NMR (500 MHz, $CDCl_3$) δ : 7.37 (t, $J = 8.0$ Hz, 2 \times 2H), 7.24 (t, $J = 7.5$ Hz, 2 \times 1H), 7.14 (m 2 \times 2H), 5.87 (m, 2 \times 1H), 5.36 (d, $J = 17.5$ Hz, 1H), 5.35 (d, $J = 17.5$ Hz, 1H), 5.24–5.11 (m, 2 \times 3H), 5.05 (m, 2 \times 1H), 4.91 (m, 2 \times 2H), 4.54–4.49 (m, 2 \times 3H), 4.35 (dd, $J = 4.5$, $J = 12.5$ Hz, 2 \times 1H), 4.21–4.02 (m, 2 \times 4H), 3.76 (m, 2 \times 2H), 3.65 (m, 2 \times 1H), 3.59 (m, 2 \times 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 2.03 (s, 3H), 2.024 (s, 3H), 2.015 (s, 2 \times 3H), 2.01 (s, 2 \times 3H), 2.00 (s, 2 \times 3H), 1.97 (s, 2 \times 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ : 170.5, 170.3, 170.2, 169.8, 169.6, 169.5, 169.3, 169.1, 168.92, 168.87, 151.1, 133.7, 133.4, 129.6, 129.3, 121.3, 118.9, 118.8, 101.2, 100.8, 100.3, 72.9, 72.8, 72.34, 72.29, 72.0, 71.7, 71.6, 71.3, 71.2, 70.4, 67.8, 61.74, 61.7, 61.6, 48.4, 47.9, 20.9, 20.74, 20.72, 20.68, 20.6; ESIHRMS Calcd. for $C_{37}H_{46}O_{20}SNa$ $[M+Na]^+$ 865.2201, found 865.2164.

2-(Phenyloxycarbonylthioxy)-3-butenyl (Methyl 4,7,8,9-tetra-O-acetyl-5-acetylamino-3,5-dideoxy-D-glycero- α -D-galacto-non-2-ulopyranosylonate) (9)—

An approximately 1:1 mixture of diastereomers with 1H NMR (500 MHz, $CDCl_3$) δ : 7.36 (t, $J = 8.0$ Hz, 2 \times 2H), 7.22 (m, 2 \times 1H), 7.15 (d, $J = 8.0$ Hz, 2 \times 2H), 5.92 (m, 2 \times 1H), 5.39 (m, 2 \times 2H), 5.32 (m, 2 \times 1H), 5.21 (m, 2 \times 1H), 4.86 (m, 2 \times 1H), 4.27 (t, $J = 12.5$ Hz, 2 \times 1H), 4.15–4.01 (m, 2 \times 6H), 3.80 (s, 3H), 3.78 (s, 3H), 3.58 (m, 2 \times 1H), 2.61 (m, 2 \times 1H), 2.12 (s, 2 \times 3H), 2.11 (s, 2 \times 3H), 2.03 (s, 2 \times 3H), 2.01 (s, 2 \times 3H), 1.864 (s, 3H), 1.861 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ : 171.2, 170.9, 170.45, 170.37, 170.2, 169.0, 168.4, 168.3, 151.4, 134.4, 134.0, 129.7, 129.3, 128.5, 126.4, 121.6, 118.7, 118.6, 98.9, 98.8, 72.8, 69.3, 68.7, 67.5, 66.5, 66.4, 62.6, 62.5, 53.11, 53.07, 49.7, 48.8, 48.5, 38.1, 23.5, 21.3, 21.10, 21.06, 21.0; ESIHRMS Calcd. for $C_{31}H_{39}NO_{15}SNa$ $[M+Na]^+$ 720.1933, found 720.1936.

General Procedure for the Conversion of Allylic Thiocarbonates to Allylic Benzothiazolyl Disulfides

The thiocarbonate (0.48 mmol) and $NH_2NH_2 \cdot H_2O$ (36 μ L, 0.72 mmol) were dissolved with stirring in DMF (3 mL), followed after 2 min, by the dropwise addition of glacial acetic acid (41 μ L, 0.72 mmol) at room temperature over 0.5 h. The resulting solution was added dropwise to a well stirred suspension of 2, 2'-dithiobis(benzothiazole) (242 mg, 0.72 mmol) in dichloromethane (3 mL) over 15 min, followed by stirring at room temperature until completion (~3 h). The solvent was evaporated and the residue was taken up in dichloromethane, and washed with water. The combined organic phases were dried, filtered, evaporated, and purified by chromatography over silica gel.

2-(Benzothiazol-2-ylidysulfanyl)-3-enyl Tetra-O-acetyl- β -D-glucopyranoside (5a)

—Yellow foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers with hexane/ethyl acetate (2:1) in 76% yield. 1H NMR (500 MHz, $CDCl_3$) δ : 7.84 (m, 2 \times 2H), 7.44 (t, $J = 7.5$ Hz, 2 \times 1H), 7.35 (t, $J = 7.5$ Hz, 2 \times 1H), 5.84 (m, 1H), 5.75 (m, 1H), 5.33–5.18 (m, 2 \times 3H), 5.10–5.01 (m, 2 \times 2H), 4.55 (d, $J = 8.0$ Hz, 1H), 4.54 (d, $J = 8.0$ Hz, 1H), 4.26–4.17 (m, 2 \times 2H), 4.12 (dt, $J = 2.0$, $J = 12.0$ Hz, 2 \times 1H), 3.85–3.75 (m, 2 \times 2H), 3.68 (m, 2 \times 1H), 2.08 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.024 (s, 3H), 2.021 (s, 3H), 2.009 (s, 3H), 2.008 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ : 172.7, 172.4, 170.1, 170.3, 169.41, 169.35, 155.0, 135.9, 132.6, 132.3, 126.4, 124.7, 122.23, 122.18, 121.2, 120.7, 120.5, 101.1, 100.8, 72.7, 72.6, 72.0, 71.0, 70.3, 70.1, 68.3, 54.2, 20.8, 20.6; ESIHRMS Calcd. for $C_{25}H_{29}NO_{10}S_3Na$ $[M+Na]^+$ 622.0846, found 622.0851.

2-(Benzothiazol-2-ylidysulfanyl)-3-enyl Tetra-O-acetyl- β -D-galactopyranoside (5b)

—Yellow foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers

with hexane/ethyl acetate (2:1) in 48% yield. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ : 7.86 (m, 2 \times 1H), 7.82 (d, $J = 8.0$ Hz, 2 \times 1H), 7.44 (m, 2 \times 1H), 7.33 (m, 2 \times 1H), 5.85 (m, 1H), 5.76 (m, 1H), 5.39 (2s, 2 \times 1H), 5.34–5.22 (m, 2 \times 3H), 5.01 (m, 2 \times 1H), 4.51 (d, $J = 8.0$ Hz, 1H), 4.50 (d, $J = 8.0$ Hz, 1H), 4.22 (m, 2 \times 1H), 4.19–4.09 (m, 2 \times 2H), 3.89 (m, 2 \times 1H), 3.85 (m, 2 \times 1H), 3.78 (d, $J = 10.0$ Hz, 1H), 3.77 (d, $J = 10.0$ Hz, 1H), 2.514 (s, 3H), 2.148 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.99 (s, 2 \times 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ : 172.7, 172.3, 170.4, 170.3, 170.2, 169.5, 169.4, 155.0, 135.9, 132.7, 132.3, 126.38, 126.35, 124.8, 124.7, 122.24, 122.18, 121.2, 120.7, 120.5, 101.6, 101.3, 70.84, 70.79, 70.7, 70.2, 70.1, 68.5, 66.9, 61.2, 54.2, 20.98, 20.95, 20.7, 20.6; ESIHRMS Calcd. for $\text{C}_{25}\text{H}_{29}\text{NO}_{10}\text{S}_3\text{Na}$ $[\text{M}+\text{Na}]^+$ 622.0846, found 622.0836.

2-(Benzothiazol-2-ylidisulfanyl)-3-enyl Hepta-O-acetyl- β -D-cellobioside (5c)—

Yellow foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers with hexane/ethyl acetate (1:1) in 50% yield. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ : 7.84 (m, 2 \times 2H), 7.43 (t, $J = 7.5$ Hz, 2 \times 1H), 7.34 (t, $J = 7.5$ Hz, 2 \times 1H), 5.83–5.70 (m, 2 \times 1H), 5.31–5.22 (m, 2 \times 2H), 5.18–5.11 (m, 2 \times 2H), 5.06 (m, 2 \times 1H), 4.93 (m, 2 \times 2H), 4.53–4.47 (m, 2 \times 3H), 4.38 (m, 1H), 4.35 (m, 1H), 4.13 (m, 2 \times 1H), 4.10–4.02 (m, 2 \times 2H), 3.85–3.73 (m, 2 \times 3H), 3.65 (m, 2 \times 1H), 3.55 (m, 2 \times 1H), 2.17 (s, 3H), 2.10 (s, 3H), 2.082 (s, 3H), 2.079 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.023 (s, 3H), 2.020 (s, 3H), 2.015 (s, 2 \times 3H), 2.00 (s, 2 \times 3H), 1.98 (s, 2 \times 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ : 172.7, 172.4, 170.5, 170.29, 170.26, 169.8, 169.61, 169.56, 169.3, 169.1, 155.0, 135.9, 132.7, 132.4, 126.3, 124.7, 122.21, 122.18, 121.2, 120.6, 120.5, 100.8, 100.6, 72.9, 72.8, 72.33, 72.26, 72.0, 71.6, 71.3, 70.2, 70.1, 67.8, 61.7, 61.6, 54.24, 54.21, 20.88, 20.83, 20.80, 20.7, 20.6; ESIHRMS Calcd. for $\text{C}_{37}\text{H}_{46}\text{O}_{18}\text{NS}_3$ $[\text{M}+\text{H}]^+$ 888.1877, found 888.1834.

2-(Benzothiazol-2-ylidisulfanyl)-3-enyl (Methyl 4,7,8,9-tetra-O-acetyl-5-acetyl-amino-3,5-dideoxy- β -glycero- α -D-galacto-non-2-ulopyranosylonate) (10)

—Yellow foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers with dichloromethane/methanol (10:1) in 60% yield. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ : 7.85 (dd, $J = 3.0, J = 8.0$ Hz, 2 \times 1H), 7.81 (d, $J = 8.0$ Hz, 2 \times 1H), 7.42 (t, $J = 8.0$ Hz, 2 \times 1H), 7.33 (t, $J = 8.0$ Hz, 2 \times 1H), 5.83 (m, 2 \times 1H), 5.40 (m, 2 \times 1H), 5.31 (m, 2 \times 2H), 5.24 (m, 2 \times 1H), 5.19 (m, 2 \times 1H), 4.89 (m, 2 \times 1H), 4.28 (m, 2 \times 1H), 4.10 (m, 2 \times 4H), 3.79 (s, 3H), 3.76 (s, 3H), 3.68 (m, 1H), 3.59 (m, 1H), 2.61 (m, 2 \times 1H), 2.12 (m, 2 \times 6H), 2.03 (m, 2 \times 6H), 1.98 (t, $J = 12.50$ Hz, 2 \times 1H), 1.88 (s, 2 \times 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ : 171.0, 170.6, 170.3, 170.1, 168.1, 155.1, 135.9, 132.8, 132.6, 126.2, 124.6, 122.1, 121.1, 120.3, 120.2, 98.7, 98.5, 69.0, 68.5, 68.4, 67.2, 65.8, 68.4, 67.2, 65.8, 65.5, 62.4, 54.8, 54.7, 52.9, 49.4, 37.9, 23.2, 21.1, 20.9, 20.8; ESIHRMS Calcd. for $\text{C}_{31}\text{H}_{38}\text{N}_2\text{O}_{19}\text{S}_3\text{Na}$ $[\text{M}+\text{Na}]^+$ 765.1429, found 765.1423.

2-(Phenoxycarbonylthioxy)-3-butenol (12)—A solution of phenyl chlorothionocarbonate (5 g, 29 mmol) in dichloromethane (3 mL) was added to a solution of (*E*)-4-(tert-butyl dimethylsiloxy)but-2-en-1-ol¹⁴ (1.95 g, 9.65 mmol), pyridine (4.6 mL, 58 mmol), and 4-(dimethylamino)pyridine (236 mg) in dichloromethane (48 mL). The yellow solution was stirred for 5 h then was poured into H_2O , and extracted with dichloromethane. The combined organic phases were dried, filtered, evaporated. The residue was taken up in toluene (200 mL) and heated at reflux for 4 h at room temperature. Evaporation of the solvent afforded a yellow syrup which was dissolved in dichloromethane/methanol (9:1), and *p*-TsOH \cdot H_2O (1.87 g, 9.65 mmol) was added in one portion. On completion, the reaction mixture was poured into H_2O , and extracted with dichloromethane. The combined organic phases were dried, filtered, evaporated and purified by chromatography over silica gel, eluting with with hexane/ethyl acetate (2:1), to give the title compound as a yellow liquid in (1.2 g, 68%). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ : 7.38 (t, $J = 8.0$ Hz, 2 \times 2H), 7.25 (t, $J = 7.5$ Hz, 2 \times 1H), 7.16 (d, $J = 8.0$ Hz, 2 \times 2H), 5.92 (m, 2 \times 1H), 5.44 (d, $J = 17.0$ Hz, 2 \times 1H), 5.32 (d, $J = 10.0$ Hz, 2 \times 1H),

4.14 (m, 2×1H), 3.89 (m, 2×2H), 1.92 (t, $J = 6.0$ Hz, 2×1H); ^{13}C NMR (125 MHz, CDCl_3) δ : 169.3, 151.3, 133.7, 129.8, 126.5, 121.5, 119.7, 64.6, 51.3; ESIHRMS Calcd. for $\text{C}_{11}\text{H}_{12}\text{O}_3\text{SNa}$ $[\text{M}+\text{Na}]^+$ 247.0405, found 247.0430.

General Procedure for the Glycosylation of 2-(Phenoxy-carbonylthioxy)-3-butenol with Glycosyl Trichloroacetimidates

The trichloroacetimidate (0.2 mmol), alcohol 12 (0.4 mmol) and activated 4 Å powdered molecular sieves were mixed in dichloromethane (2 mL) and stirred at room temperature for 0.5 h before TMSOTf (0.06 mmol) was added at 0 °C. The reaction mixture was allowed to warm to room temperature, and stirred for 2–4 h, when TLC showed the donor to have been consumed. 4-(dimethylamino)pyridine (0.4 mmol) and Ac_2O (0.4 mmol) were added at 0 °C and stirring continued for 4 h at room temperature before saturated aqueous NaHCO_3 was added at 0 °C, and the reaction mixture was filtered, and washed with brine. The organic layer was dried and concentrated under reduced pressure and the glycosides were isolated by silica gel column chromatography (hexane/ethyl acetate from 95/5 to 2/1).

General Procedure for the Glycosylation of 2-(Benzothiazol-2-yl-disulfanyl)-but-3-enol with Glycosyl Trichloroacetimidates

The trichloroacetimidate (0.2 mmol), 2-(benzothiazol-2-yl-disulfanyl)-but-3-en-1-ol 1c (0.4 mmol), and activated 4 Å powdered molecular sieves were mixed in dichloromethane (2 mL) and stirred at room temperature for 0.5 h before $\text{Zn}(\text{OTf})_2$ (74 mg, 0.2 mmol) was added at 0 °C. The reaction mixture was allowed to warm to room temperature and was stirred for 8–12 h until TLC indicated consumption of the donor. 15 The reaction mixture was quenched with saturated aqueous NaHCO_3 at 0 °C, filtered, and washed with brine. The organic layer was dried and concentrated under reduced pressure, and the glycosides were isolated by silica gel column chromatography (hexane/ethyl acetate from 95/5 to 2/1).

General Procedure for the Ligation of Protected Neoglycosyl Donors with Protected Peptides

A solution of cysteine containing peptide (0.05 mmol) and neoglycosyl donor (0.075 mmol) in methanol/acetonitrile (0.5 mL/0.5 mL) was stirred at room temperature until TLC indicated completion, after which triphenylphosphine (39 mg, 0.15 mmol) was added and the reaction mixture was stirred at room temperature for 10–24 h. The solution was evaporated and the mixture purified by chromatography eluting with dichloromethane/methanol (100/1).

S-[4-(Tetra-O-acetyl- β -D-glucopyranosyloxy)-2E-butenyl] N-(t-Butyloxycarbonyl)- γ -L-Glu-(α -OMe)-L-Cys-Gly-OMe (16)—79% yield, $[\alpha]_{\text{D}}^{23} -40.8^\circ$ (c , 0.2, MeOH); ^1H NMR (500 MHz, CDCl_3) δ : 5.75 (m, 2H), 5.27 (t, $J = 9.5$ Hz, 1H), 5.04 (t, $J = 10.0$ Hz, 1H), 4.92 (m, 1H), 4.76 (d, $J = 8.0$ Hz, 1H), 4.73 (m, 1H), 4.30 (m, 2H), 4.16 (m, 3H), 3.98 (d, $J = 5.5$ Hz, 2H), 3.88 (m, 1H), 3.73 (s, 6H), 3.40 (m, 2H), 3.21 (dd, $J = 5.0$ Hz, $J = 14.0$ Hz, 1H), 2.91 (m, 1H), 2.40 (t, $J = 7.5$ Hz, 2H), 2.14 (m, 1H), 2.08 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.93 (m, 1H), 1.45 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ : 172.94, 172.90, 171.2, 170.8, 170.6, 170.0, 169.54, 169.46, 155.8, 129.7, 128.8, 99.5, 80.3, 72.8, 71.7, 71.4, 69.1, 68.4, 62.0, 60.4, 52.6, 52.5, 52.44, 52.36, 41.3, 33.6, 32.5, 32.2, 28.9, 28.7, 28.3, 27.8, 21.1, 20.8, 20.7; ESIHRMS Calcd. for $\text{C}_{35}\text{H}_{53}\text{N}_3\text{O}_{18}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 858.2943, found 858.2936.

S-[4-(Tetra-O-acetyl- β -D-galactopyranosyloxy)-2E-butenyl] N-(t-Butyloxycarbonyl)- γ -L-Glu-(α -OMe)-L-Cys-Gly-OMe (17)—67% yield, $[\alpha]_{\text{D}}^{23} -36.6^\circ$ (c , 0.1, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 5.70 (m, 2H), 5.37 (m, 1H), 5.20 (dd, $J = 3.5$ Hz, $J = 11.0$ Hz, 1H), 5.09 (m, 1H), 4.74 (d, $J = 7.5$ Hz, 1H), 4.54 (m, 1H), 4.29 (m, 1H), 4.14 (m, 5H), 3.722 (s, 3H), 3.716 (s, 3H), 3.31 (m, 2H), 2.98 (dd, $J = 5.5$ Hz, $J = 14.0$ Hz, 1H),

2.69 (m, 1H), 2.39 (t, $J = 7.5$ Hz, 2H), 2.14 (s, 3H), 2.13 (m, 1H), 2.06 (s, 3H), 2.04 (s, 3H), 1.94 (s, 3H), 1.93 (m, 1H), 1.44 (s, 9H); ^{13}C NMR (125 MHz, CD_3OD) δ : 173.5, 173.2, 171.9, 170.8, 170.7, 170.2, 170.13, 170.10, 170.0, 156.7, 129.6, 128.6, 99.2, 79.3, 71.0, 70.4, 69.1, 68.3, 67.6, 61.3, 53.1, 52.4, 51.4, 51.3, 40.5, 32.6, 31.8, 31.5, 27.3, 27.0, 19.4, 19.3, 19.1; ESIHRMS Calcd. for $\text{C}_{35}\text{H}_{53}\text{N}_3\text{O}_{18}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 858.2943, found 858.2940.

S-[4-(Hepta-O-acetyl- β -D-cellobiosyloxy)-2E-butenyl] N-(*t*-Butyloxycarbonyl)- γ -L-Glu-(α -OMe)-L-Cys-Gly-OMe (18)—70% yield, $[\alpha]_{\text{D}}^{21} -15.4^\circ$ (c , 0.7, CHCl_3); ^1H NMR (500 MHz, CD_3OD) δ : 5.69-5.61 (2H, m), 5.24-5.16 (m, 2H), 5.00 (t, $J = 9.6$ Hz, 1H), 5.09 (m, 1H), 4.80 (t, $J = 8.4$ Hz, 2H), 4.70 (dd, $J = 2.4$, $J = 8.0$ Hz, 1H), 4.61 (dd, $J = 4.0$, $J = 8.0$ Hz, 1H), 4.53 (m, 2H), 4.39 (m, 1H), 4.26 (m, 1H), 4.14 (m, 3H), 4.04 (dd, $J = 2.0$, $J = 12.4$ Hz, 1H), 3.97 (s, 2H), 3.89-3.81 (m, 2H), 3.78 (m, 1H), 3.72 (s, 3H), 3.71 (s, 3H), 3.18 (m, 2H), 2.96 (m, 1H), 2.67 (m, 1H), 2.37 (t, $J = 7.4$ Hz, 2H), 2.12 (m, 4H), 2.05 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.93 (m, 4H), 1.43 (s, 9H); ^{13}C NMR (125 MHz, CD_3OD) δ : 173.7, 173.3, 171.8, 171.7, 171.2, 171.0, 170.7, 170.4, 170.1, 170.0, 169.8, 156.5, 133.5, 126.1, 100.7, 99.0, 79.5, 76.9, 73.3, 73.1, 72.8, 71.9, 71.8, 71.7, 68.1, 64.1, 62.4, 61.6, 57.5, 55.74, 55.70, 53.3, 51.6, 51.5, 40.8, 40.7, 31.7, 27.6, 27.2, 25.8, 19.8, 19.6, 19.53, 19.5, 19.40, 19.38; ESIHRMS Calcd. for $\text{C}_{47}\text{H}_{69}\text{N}_3\text{O}_{26}\text{SNa}$ $[\text{M}+\text{Na}]^+$ 1146.3788, found 1146.3786.

S-[4-(Tetra-O-acetyl- β -D-glucopyranosyloxy)-2E-butenyl] N-(*t*-Butyloxycarbonyl)-L-Cys-L-Ala-L-Trp-OMe (20)—59% Yield, $[\alpha]_{\text{D}}^{23} -19.9^\circ$ (c , 0.9, MeOH); ^1H NMR (500 MHz, CD_3OD) δ : 7.50 (d, $J = 8.0$ Hz, 1H), 7.33 (d, $J = 8.0$ Hz, 1H), 7.09 (m, 2H), 7.02 (m, 1H), 5.63 (m, 2H), 5.25 (t, $J = 10.0$ Hz, 1H), 4.99 (t, $J = 10.0$ Hz, 1H), 4.73 (m, 1H), 4.64 (d, $J = 8.0$ Hz, 1H), 4.42 (m, 1H), 4.24 (m, 2H), 4.17 (m, 1H), 4.09 (m, 3H), 3.76 (m, 1H), 3.64 (s, 3H), 3.27 (m, 1H), 3.22 (m, 1H), 3.10 (d, $J = 2.5$ Hz, 1H), 2.81 (m, 1H), 2.04 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.44 (s, 9H), 1.32 (d, $J = 7.0$ Hz, 3H); ^{13}C NMR (125 MHz, CD_3OD) δ : 173.0, 172.2, 171.6, 171.0, 170.3, 169.9, 169.8, 156.3, 136.6, 129.3, 128.5, 127.4, 123.3, 121.1, 118.5, 117.8, 111.0, 109.1, 99.2, 79.5, 72.9, 71.5, 71.3, 68.6, 68.4, 61.7, 60.2, 53.8, 53.4, 51.3, 48.9, 32.7, 32.4, 27.3, 27.1, 19.5, 19.4, 19.3, 19.2, 16.8, 13.1; ESIHRMS Calcd. for $\text{C}_{41}\text{H}_{57}\text{N}_4\text{O}_{16}\text{S}$ $[\text{M}+\text{H}]^+$ 893.3485, found 893.3488.

S-[4-(Tetra-O-acetyl- β -D-galactopyranosyloxy)-2E-butenyl] N-(*t*-Butyloxycarbonyl)-L-Cys-L-Ala-L-Trp-OMe (21)—66% yield, $[\alpha]_{\text{D}}^{21} -10.5^\circ$ (c , 1.1, MeOH); ^1H NMR (500 MHz, CDCl_3) δ : 8.61 (br. s, 1H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.35 (d, $J = 8.0$ Hz, 1H), 7.16 (t, $J = 7.5$ Hz, 1H), 7.09 (t, $J = 7.5$ Hz, 1H), 7.00 (s, 1H), 6.83 (d, $J = 7.5$ Hz, 1H), 6.79 (d, $J = 7.0$ Hz, 1H), 5.63 (m, 2H), 5.38 (d, $J = 3.0$ Hz, 1H), 5.32 (d, $J = 7.0$ Hz, 1H), 5.23 (m, 1H), 5.13 (dd, $J = 3.5$, $J = 10.5$ Hz, 1H), 4.88 (m, 1H), 4.61 (d, $J = 7.5$ Hz, 1H), 4.50 (t, $J = 7.2$ Hz, 1H), 4.33 (d, $J = 11.5$ Hz, 1H), 4.20 (m, 2H), 4.11 (m, 2H), 4.01 (m, 2H), 3.69 (s, 3H), 3.42 (dd, $J = 5.0$, $J = 15.0$ Hz, 1H), 3.28 (dd, $J = 5.5$, $J = 14.5$ Hz, 1H), 3.07 (d, $J = 4.5$ Hz, 2H), 2.75 (d, $J = 6.0$ Hz, 2H), 2.11 (s, 3H), 2.06 (s, 3H), 2.01 (s, 3H), 1.95 (s, 3H), 1.47 (s, 9H), 1.34 (d, $J = 7.0$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ : 172.1, 171.5, 170.8, 170.5, 170.0, 136.3, 129.8, 129.1, 127.7, 123.6, 122.3, 119.7, 118.6, 111.6, 109.7, 99.9, 80.7, 71.1, 70.7, 69.3, 69.1, 67.4, 61.6, 53.0, 52.7, 49.1, 33.8, 33.2, 29.9, 28.5, 27.6, 21.1, 20.88, 20.85, 20.8, 18.1; ESIHRMS Calcd. for $\text{C}_{41}\text{H}_{57}\text{N}_4\text{O}_{16}\text{S}$ $[\text{M}+\text{H}]^+$ 893.3485, found 893.3480.

General Procedure for the Ligation of Protected Neoglycosyl Donors with Glutathione

A solution of glutathione (0.05 mmol) and neoglycosyl donor (0.075 mmol) in Tris buffer (pH 8.0)/acetonitrile (0.5 mL/0.5 mL) was stirred at room temperature until completion.

Triphenylphosphine (39 mg, 0.15 mmol) dissolved in tetrahydrofuran (0.5 mL) was added and the reaction mixture was stirred at room temperature for 10–24 h. The solution was evaporated and the residue purified by reverse phase HPLC using a gradient of 50% A to 100% A

developed over 50 min (A, 0.1% TFA/CH₃CN; B, 0.1% TFA/H₂O; column: Varian Microsorb C₁₈ 250 × 21.4 mm; flow rate: 8mL/min; UV detection: 215nm).

S-[4-(Tetra-O-acetyl-β-D-glucopyranosyloxy)-2E-butenyl] γ-L-Glu-L-Cys-Gly (23)—75% yield, [α]_D²⁴ -13.3° (c, 0.6, MeOH); ¹H NMR (500 MHz, D₂O) δ: 5.60 (m, 2H), 5.24 (t, *J* = 9.5 Hz, 1H), 4.98 (t, *J* = 9.5 Hz, 1H), 4.84 (t, *J* = 8.5 Hz, 1H), 4.76 (d, *J* = 8.5 Hz, 1H), 4.42 (m, 1H), 4.23 (m, 2H), 4.10 (m, 2H), 3.91 (m, 3H), 3.85 (t, *J* = 6.5 Hz, 1H), 3.10 (d, *J* = 6.0 Hz, 2H), 2.87 (dd, *J* = 5.4, *J* = 14.0 Hz, 1H), 2.68 (m, 1H), 2.44 (m, 2H), 2.08 (m, 2H), 1.99 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H); ¹³C NMR (125 MHz, D₂O) δ: 174.3, 173.7, 173.1, 172.85, 172.77, 172.66, 171.9, 130.6, 128.2, 98.8, 73.1, 71.5, 71.1, 69.5, 68.3, 61.8, 52.8, 52.5, 41.0, 32.6, 31.4, 30.9, 25.5, 20.14, 20.11, 20.03, 19.99; ESIHRMS Calcd. for C₂₈H₄₁N₃O₁₆SNa [M+Na]⁺ 730.2105, found 730.2102.

S-[4-(Methyl 4,7,8,9-tetra-O-acetyl-5-acetyl-amino-3,5-dideoxy-D-glycero-α-D-galacto-non-2-ulopyranosylonate)-2E-butenyl] γ-L-Glu-L-Cys-Gly (24)—71% yield, [α]_D²⁴ -9.2° (c, 0.6, MeOH/H₂O, 1:1); ¹H NMR (500 MHz, D₂O) δ: 5.64 (m, 2H), 5.29 (m, 2H), 4.80 (m, 2H), 4.45 (m, 1H), 4.26 (m, 1H), 4.15 (m, 3H), 3.99 (t, *J* = 6.5 Hz, 1H), 3.95 (m, 1H), 3.92 (s, 2H), 3.83 (t, *J* = 10.5 Hz, 1H), 3.77 (s, 3H), 3.13 (d, *J* = 6.5 Hz, 2H), 2.89 (dd, *J* = 5.5, *J* = 14.0 Hz, 2H), 2.71 (m, 1H), 2.63 (dd, *J* = 5.0, *J* = 13.0 Hz, 1H), 2.50 (m, 2H), 2.16 (m, 2H), 2.11 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H), 1.94 (s, 3H), 1.82 (s, 3H); ¹³C NMR (125 MHz, D₂O) δ: 175.1, 174.5, 173.9, 173.7, 173.6, 173.2, 173.1, 172.6, 169.0, 132.7, 126.5, 98.8, 71.8, 69.4, 68.5, 67.5, 62.4, 57.4, 55.8, 53.9, 53.6, 49.0, 41.6, 37.2, 26.1, 25.5, 22.0, 20.7, 20.4, 20.3; ESIHRMS Calcd. for C₃₄H₅₀N₄O₁₉SNa [M+Na]⁺ 873.2688, found 873.2699.

General Procedure for Preparation of Deprotected Neoglycosyl Donors from Acetylated Allylic Thiocarbonates

The peracetyl glycosyl thiolcarbonate (0.2 mmol) was dissolved in MeOH (1 mL) at 0 °C with stirring and 1M KOH in MeOH (1.2 mmol-2.1 mmol, 1.5 eq per acetate group) was added dropwise. After 10–15 min, the pH of the reaction mixture was adjusted 7 by careful addition of Amberlyst-15. The reaction mixture was then filtered and the filtrate was added dropwise over 15 min to a well stirred solution of 2,2'-dipyridyl disulfide (68 mg, 0.3 mmol) in MeOH (1 mL) at room temperature, and the resulting solution stirred until completion (TLC, ~3 h). The solvent was removed in vacuo and the residue taken up in H₂O and washed with ether several times. Evaporation of the aqueous phase followed by chromatographic purification gave the products.

2-(2-Pyridyldisulfanyl)-3-enyl β-D-Galactopyranoside (25b)—White foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers with dichloromethane/methanol (20:1) in 92% yield, ¹H NMR (500 MHz, CD₃OD) δ: 8.36 (m, 2×1H), 7.94 (m, 2×1H), 7.81 (m, 2×1H), 7.20 (m, 2×1H), 5.86 (m, 1H), 5.81 (m, 1H), 5.23 (m, 2×1H), 5.14 (d, *J* = 10.5 Hz, 2×1H), 4.24 (m, 2×1H), 4.13 (m, 2×1H), 3.80 (m, 2×3H), 3.72 (m, 2×2H), 3.55 (2×1H, m), 3.47 (m, 2×2H); ¹³C NMR (125 MHz, CD₃OD) δ: 160.6, 148.8, 138.0, 134.24, 134.20, 121.0, 120.4, 118.4, 118.2, 104.04, 103.96, 75.6, 73.8, 71.3, 70.1, 69.1, 61.3, 61.2, 54.3; ESIHRMS Calcd. for C₁₅H₂₁NO₆S₂Na [M+Na]⁺ 398.0708, found 398.0706.

2-(2-Pyridyldisulfanyl)-3-enyl β-D-Cellobioside (25c)—White foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers with dichloromethane/methanol (15:1) in 92% yield, ¹H NMR (500 MHz, CD₃OD) δ: 8.53 (m, 2×1H), 8.13 (m, 2×2H), 7.50 (m, 2×1H), 5.86 (m, 2×1H), 5.28 (m, 2×1H), 5.18 (m, 2×1H), 4.41 (d, *J* = 7.5 Hz, 2×1H), 4.32 (dd, *J* = 8.0, *J* = 17.0 Hz, 2×1H), 4.16 (m, 1H), 4.09 (m, 1H), 3.90 (m, 2×4H), 3.80 (m, 2×2H), 3.66 (m, 2×1H), 3.52 (m, 2×2H), 3.36 (m, 2×3H), 3.25 (m, 2×2H); ¹³C NMR (125 MHz, CD₃OD) δ: 160.6, 148.8, 138.0, 134.2, 134.1, 121.1, 120.4, 118.5, 118.3, 103.4, 103.2, 79.5, 76.9, 76.7,

75.4, 75.2, 73.7, 73.6, 70.2, 70.1, 61.3, 60.7, 54.2, 54.1; ESIHRMS Calcd. for $C_{21}H_{31}NO_{11}S_2Na$ $[M+Na]^+$ 560.1236, found 560.1255.

2-(2-Pyridyldisulfanyl)-3-enyl (Methyl 5-acetylamino-3,5-dideoxy- β -glycero- α - β -galactono-2-ulopyranosylonate (26))—White foam, eluted from silica gel as an approximately 1:1 mixture of diastereomers with dichloromethane/methanol (20:1) in 78% yield, 1H NMR (500 MHz, CD_3OD) δ : 8.37 (m, 2 \times 1H), 7.87 (m, 2 \times 1H), 7.81 (m, 2 \times 1H), 7.21 (m, 2 \times 1H), 5.77 (m, 2 \times 1H), 5.20 (m, 2 \times 2H), 4.05 (m, 2 \times 1H), 3.82 (m, 2 \times 2H), 3.80 (s, 3H), 3.78 (s, 3H), 3.64 (m, 2 \times 4H), 3.54 (m, 2 \times 1H), 3.49 (m, 2 \times 1H), 2.66 (m, 2 \times 1H), 1.994 (s, 3H), 1.991 (s, 3H), 1.71 (m, 2 \times 1H); ^{13}C NMR (125 MHz, CD_3OD) δ : 174.0, 169.47, 169.49, 160.5, 160.4, 148.97, 148.89, 138.0, 133.91, 133.86, 121.2, 121.1, 120.24, 120.21, 118.7, 118.5, 99.05, 99.00, 73.9, 71.2, 71.1, 68.98, 68.9, 67.3, 64.9, 64.87, 63.6, 63.5, 54.2, 53.9, 52.6, 52.3, 40.3, 40.28, 21.5; ESIHRMS Calcd. for $C_{21}H_{30}N_2O_9S_2Na$ $[M+Na]^+$ 541.1290, found 541.1305.

General Procedure for the Ligation of Unprotected Neoglycosyl Donors with Glutathione

A solution of glutathione (21.7 mg, 0.07 mmol) and neoglycosyl donor (0.11 mmol) in phosphate buffer (pH 8.0)/acetonitrile (0.5 mL/0.5 mL) was stirred at room temperature until completion (12–24 h). Triphenylphosphine (27.5 mg, 0.11 mmol) dissolved in THF (0.1 mL) was added and the reaction mixture was stirred at room temperature for 10–24 h. The solution was evaporated and the mixture purified by reverse phase HPLC using a gradient of 100% B to 50% B developed over 50 min (A, 0.1% TFA/ CH_3CN ; B, 0.1% TFA/ H_2O ; column: Varian Microsorb C_{18} 250 \times 21.4 mm; flow rate: 8 mL/min; UV detection: 215 nm).

S-[4-(β - β -Galactopyranosyloxy)-2E-butenyl] γ -L-Glu-L-Cys-Gly (27)—90% yield, $[\alpha]_D^{23}$ -18.9° (c, 1.0, MeOH); 1H NMR (400 MHz, D_2O) δ : 5.77 (m, 2H), 4.52 (m, 1H), 4.38 (d, $J = 8.4$ Hz, 1H), 4.35 (dd, $J = 3.2$, $J = 12.0$ Hz, 1H), 4.20 (m, 1H), 4.08 (t, $J = 6.4$ Hz, 1H), 3.99 (s, 2H), 3.88 (d, $J = 3.2$ Hz, 1H), 3.73 (m, 2H), 3.61 (m, 2H), 3.48 (m, 1H), 3.20 (d, $J = 5.6$ Hz, 2H), 2.96 (m, 1H), 2.79 (m, 1H), 2.56 (m, 2H), 2.22 (m, 2H); ^{13}C NMR (100 MHz, D_2O) δ : 174.5, 173.13, 173.07, 171.7, 130.7, 130.0, 102.0, 75.4, 73.1, 71.0, 69.7, 68.91, 61.2, 53.2, 52.4, 41.4, 33.0, 31.8, 31.1, 25.7; ESIHRMS Calcd. for $C_{20}H_{31}N_3O_{12}S$ $[M-H]^-$ 538.1707, found 538.1689.

S-[4-(β - β -Cellobiosyloxy)-2E-butenyl] γ -L-Glu-L-Cys-Gly (28)—92% yield, $[\alpha]_D^{23}$ -0.4° (c, 1.7, MeOH); 1H NMR (400 MHz, CD_3OD) δ : 5.76 (m, 2H), 4.57 (m, 1H), 4.40 (d, $J = 8.0$ Hz, 1H), 4.35 (m, 2H), 4.16 (m, 1H), 4.05 (m, 1H), 3.94 (s, 2H), 3.86 (m, 2H), 3.66 (m, 1H), 3.54 (m, 2H), 3.39 (m, 2H), 3.31 (m, 3H), 3.25 (m, 2H), 3.19 (d, $J = 5.6$ Hz, 2H), 2.95 (m, 1H), 2.71 (m, 1H), 2.57 (m, 2H), 2.20 (m, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ : 173.2, 171.9, 171.5, 170.3, 129.6, 129.3, 103.5, 101.9, 79.6, 76.9, 76.7, 75.3, 75.2, 73.7, 73.6, 70.2, 68.9, 61.2, 60.6, 53.0, 52.3, 48.7, 40.6, 33.1, 32.2, 31.1, 25.9; ESIHRMS Calcd. for $C_{26}H_{42}N_3O_{17}S$ $[M-H]^-$ 700.2235, found 700.2229.

S-[4-(Methyl (5-acetamido-3,5-dideoxy- β -glycero- α - β -galactono-2-ulopyranoside)onate)-2E-butenyl] γ -L-Glu-L-Cys-Gly (29)—94% yield, $[\alpha]_D^{23}$ -13.8° (c, 1.4, MeOH); 1H NMR (400 MHz, D_2O) δ : 5.77 (m, 2H), 4.51 (m, 1H), 4.27 (m, 1H), 4.06 (m, 2H), 3.99 (s, 2H), 3.83 (m, 7H), 3.71 (m, 1H), 3.62 (m, 1H), 3.52 (d, $J = 9.2$ Hz, 1H), 3.18 (d, $J = 5.6$ Hz, 1H), 2.94 (m, 1H), 2.77 (m, 1H), 2.67 (m, 1H), 2.56 (m, 2H), 2.22 (m, 2H), 2.00 (s, 3H), 1.78 (t, $J = 12.0$ Hz, 1H); ^{13}C NMR (100 MHz, D_2O) δ : 175.3, 174.5, 173.1, 173.0, 171.7, 170.3, 130.5, 128.7, 99.1, 73.2, 70.9, 68.5, 67.4, 65.0, 63.4, 53.7, 53.2, 52.4, 52.0, 41.3, 39.6, 33.0, 31.8, 31.1, 25.7, 22.3; ESIHRMS Calcd. for $C_{26}H_{42}N_4O_{15}SNa$ $[M+Na]^+$ 705.2265, found 705.2265.

t-Butyl 3-Acetylthio-4-pentenoate (32)—Diisopropyl azodicarboxylate (5.1 mL, 26 mmol) was added to a stirred solution of triphenylphosphine (6.85g, 26 mmol) in tetrahydrofuran (46 mL) at 0 °C over 0.5 h, resulting in the formation of a white precipitate. A solution of alcohol **31**¹⁶ (3.0 g, 17.4 mmol) and thiolacetic acid (1.87 mL, 26 mmol) in tetrahydrofuran (20 mL) was then added dropwise and the mixture was stirred for 1 h at 0°C and at room temperature for 13 h resulting in a clear yellow solution. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried, filtered, evaporated and purified by chromatography (eluting with hexane/ethyl acetate, 10:1) to give **32** (3.06g, 76%) as yellow oil; ¹H NMR (500 MHz, CDCl₃) δ: 5.86 (m, 2×1H), 5.26 (d, *J* = 17.0 Hz, 2×1H), 5.10 (d, *J* = 10.5 Hz, 2×1H), 4.42 (q, *J* = 7.5 Hz, 2×1H), 2.63 (m, 2×2H), 2.31 (s, 2×3H), 1.43(s, 2×9H); ¹³C NMR (125 MHz, CDCl₃) δ: 195.4, 169.8, 136.6, 116.7, 81.4, 42.5, 40.2, 30.8, 28.3; ESIHRMS Calcd. for C₁₁H₁₈O₃SNa [M+Na]⁺ 253.0874, found 253.0895.

t-Butyl 3-[(2-Pyridinyl)disulfanyl]-4-pentenoate (33)—Lithium hydroxide monohydrate (30 mg, 0.71 mmol) was added in one portion to a stirred solution of thiolacetate **32** (163 mg, 0.71 mmol) in methanol (3.5 mL) at 0 °C. After 0.5 h the pH of the solution was adjusted to 7 with 3M HCl, and the resulting solution was added dropwise to a stirred solution of 2,2'-dipyridyl disulfide (239 mg, 1.06 mmol) in dichloromethane (3 mL) over 15 min. After stirring for 3 h, the solvent was removed. The residue was dissolved in ethyl acetate and washed with water. The organic layer was dried, filtered, evaporated and purified by chromatography on silica gel¹⁷ (eluting with hexane/ethyl acetate, 10:1) to afford **33** (144 mg, 68%) as yellow oil. ¹H NMR (500 MHz, CDCl₃) δ: 8.44 (dd, *J* = 0.5, *J* = 4.5 Hz, 2×1H), 7.72 (d, *J* = 7.5 Hz, 2×1H), 7.63 (dt, *J* = 2.0, *J* = 7.5 Hz, 2×1H), 7.08 (dt, *J* = 1.0, *J* = 7.5 Hz, 2×1H), 5.76 (m, 2×1H), 5.18 (d, *J* = 17.0 Hz, 2×1H), 5.10 (d, *J* = 10.0 Hz, 2×1H), 3.86 (q, *J* = 8.5 Hz, 2×1H), 2.77 (dd, *J* = 6.5, *J* = 15.5 Hz, 2×1H), 2.59 (dd, *J* = 8.5, *J* = 16.0 Hz, 2×1H), 1.43(s, 2×9H); ¹³C NMR (125 MHz, CDCl₃) δ: 170.0, 160.6, 149.6, 137.1, 135.6, 120.9, 120.0, 118.3, 81.5, 50.0, 39.8, 28.3; ESIHRMS Calcd. for C₁₄H₁₉NO₂S₂Na [M+Na]⁺ 320.0755, found 320.0766.

3-[(2-Pyridinyl)disulfanyl]-4-pentenoic Acid (34)—Trifluoroacetic acid (1.36 mL, 17.5 mmol) was added dropwise over 20 min into a stirred solution of ester **33** (208 mg, 0.7 mmol) in dichloromethane (1.4 mL) at 0 °C. The reaction mixture was stirred for 4–5 h at room temperature, then concentrated, taken up in toluene, and concentrated again to afford **34** (169 mg, 100%) as yellow syrup; ¹H NMR (400 MHz, CDCl₃) δ: 12.34 (br. s, 2×1H), 8.59 (d, *J* = 4.8 Hz, 2×1H), 7.87 (m, 2×2H), 7.35 (t, *J* = 6.0 Hz, 2×1H), 5.80 (m, 2×1H), 5.20 (m, 2×2H), 3.93 (q, *J* = 7.2 Hz, 2×1H), 2.82(m, 2×2H); ¹³C NMR (100 MHz, CDCl₃) δ: 159.0, 147.1, 140.3, 134.7, 122.7, 122.4, 119.2, 50.0, 38.4, 29.9; ESIHRMS Calcd. for C₁₀H₁₁NO₂S₂Na [M+Na]⁺ 264.0129, found 264.0147.

General Procedure for Formation of *N*-Glycosyl 3-[(2-Pyridinyl)disulfanyl]-4-pentenamides¹⁸

A solution of β-D-glucopyranosyl azide or 2-acetamido-2-deoxy-β-D-glucopyranosyl azide (1.18 mmol) in *n*-methylpyrrolidone (4 mL) was stirred with 10% Pd/C under H₂ (1 atm) at room temperature until TLC indicated completion (~5 h). After filtration the reaction mixture was added dropwise over 0.5 h to a stirred, premixed solution of *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU) (231 mg, 0.59 mmol) and diisopropylethylamine (202 μL, 1.18 mmol) and acid **34** (142 mg, 0.59 mmol) in DMF (1.7 mL) at 0 °C. The reaction mixture was stirred at room temperature overnight, then concentrated and the residue taken up in toluene and concentrated again to give yellow oil, which was lyophilized to remove *N*-methylpyrrolidone and then subjected to flash chromatography to afford the pure *N*-glycosyl amide.

***N*-(β-D-Glucopyranosyl) 3-[(2-Pyridinyl)disulfanyl]-4-pentenamide (36a)**—White foam, eluted from silica gel with dichloromethane/methanol (3:1) as an approximately 1/1 mixture of diastereomers in 46% yield. ¹H NMR (400 MHz, D₂O) δ: 8.34 (d, *J* = 4.8 Hz, 2×1H), 7.79 (m, 2×2H), 7.25 (m, 2×1H), 5.73 (m, 2×1H), 5.13 (d, *J* = 17.2 Hz, 2×1H), 5.04 (d, *J* = 9.6 Hz, 2×1H), 3.87 (m, 2×2H), 3.69 (m, 2×1H), 3.50 (m, 2×2H), 3.35 (m, 2×2H), 2.77 (m, 2×2H); ¹³C NMR (100 MHz, D₂O) δ: 174.4, 159.0, 149.1, 138.8, 135.1, 122.2, 121.8, 118.6, 118.5, 79.6, 77.9, 76.8, 72.0, 69.5, 60.8, 49.93, 49.86, 39.5, 39.4; ESIHRMS Calcd. for C₁₆H₂₂N₂O₆S₂Na [M+Na]⁺ 425.0817, found 428.0824.

***N*-(2-Acetamido-2-deoxy-β-D-Glucopyranosyl) 3-[(2-Pyridinyl)disulfanyl]-4-pentenamide (36b)**—White foam, eluted from silica gel with dichloromethane/methanol (3:1) as an approximately 1/1 mixture of diastereomers in 43% yield. ¹H NMR (400 MHz, D₂O) δ: 8.37 (m, 2×1H), 7.83 (m, 2×2H), 7.28 (m, 2×1H), 5.72 (m, 2×1H), 5.07 (m, 2×3H), 3.88 (m, 2×2H), 3.77 (m, 2×2H), 3.60 (m, 2×1H), 3.35 (m, 2×2H), 2.74 (m, 2×2H), 1.98 (s, 3H), 1.97 (s, 3H); ¹³C NMR (100 MHz, CD₃OD) δ: 173.1, 173.0, 171.5, 160.24, 160.15, 149.0, 148.9, 137.91, 137.87, 135.6, 135.5, 121.2, 121.1, 120.20, 120.15, 117.5, 117.3, 79.1, 79.0, 78.62, 78.59, 75.20, 75.16, 70.61, 70.58, 61.5, 54.9, 50.2, 50.0, 39.7, 39.6, 21.9, 21.8; ESIHRMS Calcd. for C₁₈H₂₅N₃O₆S₂Na [M+Na]⁺ 466.1082, found 466.1100.

General Procedure for Ligation of *N*-Glycosyl 3-[(2-Pyridinyl)disulfanyl]-4-pentenamides with Peptides

A solution of cysteine containing peptide (0.05 mmol) and the *N*-glycosyl amide (0.075 mmol) in phosphate buffer (pH 8.0)/acetonitrile (0.5 mL/0.5 mL) was stirred at room temperature until completion (12–24 h). Triphenylphosphine (26 mg, 0.1 mmol) dissolved in THF (0.1 mL) then was added and the reaction mixture was stirred at room temperature for 10–24 h. The solution was evaporated and the residue purified by reverse phase HPLC using a gradient of 100% B to 50% B developed over 70 min (A, 0.1% TFA/CH₃CN; B, 0.1% TFA/H₂O; column: Varian Microsorb C₁₈ 250 × 21.4 mm; flow rate: 8mL/min; UV detection: 215nm).

***S*-[*N*-(β-D-Glucopyranosyl)-5-carboxamido-2*E*-butenyl] γ-L-Glu-L-Cys-Gly (37)**—70% yield, [α]_D²³ -18.5° (*c*, 0.6, MeOH/H₂O 1:1); ¹H NMR (400 MHz, D₂O) δ: 5.66 (m, 2H), 4.94 (d, *J* = 8.8 Hz, 1H), 4.53 (m, 1H), 4.04 (t, *J* = 6.4 Hz, 1H), 4.00 (s, 2H), 3.86 (m, 1H), 3.70 (dd, *J* = 4.8, *J* = 12.0 Hz, 1H), 3.51 (m, 1H), 3.59 (t, *J* = 8.4 Hz, 1H), 3.38 (m, 2H), 3.27 (m, 2H), 3.20 (d, *J* = 6.4 Hz, 2H), 3.11 (d, *J* = 4.8 Hz, 1H), 2.97 (dd, *J* = 5.4, *J* = 14.2 Hz, 1H), 2.80 (m, 1H), 2.57 (m, 2H), 2.22 (m, 2H); ¹³C NMR (100 MHz, D₂O) δ: 176.1, 174.6, 173.2, 173.1, 172.2, 130.6, 126.1, 79.6, 77.9, 76.8, 72.0, 69.5, 60.8, 53.2, 52.8, 47.8, 41.4, 39.2, 33.2, 31.6, 31.2, 25.9; ESIHRMS Calcd. for C₂₁H₃₅N₄O₁₂S [M+H]⁺ 567.1972, found 567.1967.

***S*-[*N*-(2-Acetamido-2-deoxy-β-D-glucopyranosyl)-5-carboxamido-2*E*-butenyl] γ-L-Glu-L-Cys-Gly (38)**—85% yield, [α]_D²³ -3.4° (*c*, 0.7, MeOH/H₂O 1:1); ¹H NMR (400 MHz, D₂O) δ: 5.52 (m, 2H), 5.03 (d, *J* = 9.6 Hz, 1H), 4.52 (m, 1H), 4.04 (t, *J* = 6.4 Hz, 1H), 4.00 (s, 2H), 3.86 (dd, *J* = 1.6, *J* = 12.0 Hz, 1H), 3.80 (t, *J* = 10.0 Hz, 1H), 3.73 (dd, *J* = 4.8, *J* = 12.0 Hz, 1H), 3.59 (t, *J* = 8.4 Hz, 1H), 3.48 (m, 2H), 3.19 (d, *J* = 5.6 Hz, 2H), 3.03 (d, *J* = 4.8 Hz, 2H), 3.00 (dd, *J* = 5.6, *J* = 14.0 Hz, 1H), 2.78 (dd, *J* = 8.8, *J* = 14.4 Hz, 1H), 2.57 (m, 2H), 2.22 (m, 2H), 1.98 (s, 3H); ¹³C NMR (100 MHz, D₂O) δ: 175.5, 175.0, 174.6, 173.2, 173.1, 130.7, 126.0, 78.8, 77.9, 74.4, 69.8, 60.8, 54.6, 53.2, 52.7, 41.4, 39.3, 33.3, 31.8, 31.2, 25.8, 22.3; ESIHRMS Calcd. for C₂₃H₃₇N₅O₁₂SNa [M+Na]⁺ 630.2057, found 630.2072.

***S*-[*N*-(2-Acetamido-2-deoxy-β-D-glucopyranosyl)-5-carboxamido-2*E*-butenyl] L-Val-L-Thr-L-Cys-Gly (40)**—70% yield, [α]_D²³ -8.9° (*c*, 0.2, MeOH/H₂O 1:1); ¹H NMR (500 MHz, D₂O) δ: 5.50 (m, 2H), 4.92 (d, *J* = 10.0 Hz, 1H), 4.45 (m, 1H), 4.32 (d, *J* = 6.5 Hz, 1H), 4.03 (m, 1H), 3.88 (s, 2H), 3.80 (d, *J* = 5.5 Hz, 1H), 3.75 (m, 1H), 3.69 (t, *J* = 10.0 Hz, 1H),

3.62 (dd, $J = 4.5$, $J = 12.0$ Hz, 1H), 3.48 (t, $J = 9.2$ Hz, 1H), 3.37 (m, 2H), 3.07 (d, $J = 6.0$ Hz, 2H), 2.92 (d, $J = 4.5$ Hz, 2H), 2.86 (d, $J = 5.0$ Hz, $J = 14.0$ Hz, 1H), 2.69 (m, 1H), 2.12 (m, 1H), 1.87 (s, 3H), 1.10 (d, $J = 6.0$ Hz, 3H), 0.90 (t, $J = 7.0$ Hz, 6H); ^{13}C NMR (125 MHz, D_2O) δ : 175.3, 174.9, 173.1, 172.3, 171.2, 169.7, 130.6, 125.8, 78.7, 77.8, 74.3, 69.7, 67.3, 60.7, 59.3, 58.6, 54.5, 52.9, 50.6, 41.4, 39.2, 30.5, 24.0, 22.2, 19.0, 17.9, 17.0; ESIHRMS Calcd. for $\text{C}_{27}\text{H}_{47}\text{N}_6\text{O}_{12}\text{S}$ $[\text{M}+\text{H}]^+$ 679.2973, found 679.2997.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgement

We thank the NIH (GM62160) for partial support of this work and Dr. Franck Brebion for help and advice in the initial stages of the project.





References

1. a) Crich D, Krishnamurthy V, Hutton TK. *J. Am. Chem. Soc* 2006;128:2544–2545. [PubMed: 16492032] b) Crich D, Zou Y, Brebion F. *J. Org. Chem* 2006;71:9172–9177. [PubMed: 17109543] c) Crich D, Krishnamurthy V, Brebion F, Karatholuvhu M, Subramanian V, Hutton TK. *J. Am. Chem. Soc* 2007;129:10282–10294. [PubMed: 17655306] d) Li Z, Wang C, Fu Y, Guo Q-X, Liu L. *J. Org. Chem* 2008;73:0000–0000.
2. a) Paulson JC, Blixt O, Collins BE. *Nature Chem. Biol* 2006;2:238–248. [PubMed: 16619023] b) Dwek RA, Butters TD. *Chem. Rev* 2002;102:283–284. c) Varki A. *Glycobiology* 1993;3:97–130. [PubMed: 8490246] Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Hart, G.; Marth, J., editors. *Essentials of Glycobiology*. Cold Spring Harbor: Cold Spring Harbor Press; 1999. e) Buskas T, Ingale S, Boons G-J. *Glycobiology* 2006;16:113R–136R. f) Werz DB, Seeberger PH. *Chem. Biol* 2007;2:661–691. Ernst, B.; Hart, GW.; Sinay, P., editors. *Carbohydrates in Chemistry and Biology*. Weinheim: Wiley-VCH; 2000. Fraser-Reid, B.; Kuniaki, T.; Thiem, J., editors. *Glycoscience: Chemistry and Chemical Biology*. Berlin: Springer-Verlag; 2001. Fukuda, M.; Hindsgaul, O., editors. *Molecular and Cellular Glycobiology*. Oxford: Oxford University Press; 2000. Demchenko, AV., editor. *Frontiers in Modern Carbohydrate Chemistry*. Washington, DC: American Chemical Society; 2007. k) Davis BG. *Chem. Rev* 2002;102:579–601. [PubMed: 11841255] l) Murrey HE, Hsieh-Wilson LC. *Chem. Rev* 2008;108:1708–1731. [PubMed: 18452339]
3. a) Yamamoto N, Tanabe Y, Okamoto R, Dawson PE, Kajihara Y. *J. Am. Chem. Soc* 2008;130:501–510. [PubMed: 18085777] b) Krauss IJ, Joyce JG, Finnefrock AC, Song HC, Dudkin VY, Geng X, Warren DJ, Chastain M, Shiver JW, Danishefsky SJ. *J. Am. Chem. Soc* 2007;129:11042–11044. [PubMed: 17711286] c) Haase C, Seitz O. *Top. Curr. Chem* 2007;267:1–36.
4. a) Stowell CP, Lee YC. *Adv. Carbohydr. Chem. Biochem* 1980;37:225–281. [PubMed: 6996450] Lee, YC.; Lee, RT., editors. *Neoglycoconjugates: Preparation and Applications*. San Diego: Academic Press; 1994. Roy, R. *Carbohydrate Chemistry*. Boons, G-J., editor. London: Blackie Academic and Professional; 1998. p. 243–321. d) Specker D, Wittman V. *Top. Curr. Chem* 2007;267:65–108.
5. a) Zhu XM, Pachamuthu K, Schmidt RR. *Org. Lett* 2004;6:1083–1085. [PubMed: 15040728] b) Pachamuthu K, Schmidt RR. *Chem. Rev* 2006;106:160–187. [PubMed: 16402775] c) Doores KJ, Gamblin DP, Davis BG. *Chem. Eur. J* 2006;12:656–665. d) Peri F, Nicotra F. *Chem Comm* 2004:623–627. [PubMed: 15010751] e) Ohnishi Y, Ichikawa M, Ichikawa Y. *Biorg. Med. Chem. Lett* 2000;10:1289–1291. f) Jobron L, Hummel G. *Org. Lett* 2000;2:2265–2267. [PubMed: 10930259] g) Cohen SB, Halcomb RL. *Org. Lett* 2001;3:405–407. [PubMed: 11428025] h) Knapp S, Myers DS. *J. Org. Chem* 2002;67:2995–2999. [PubMed: 11975558] i) Zhu XM, Schmidt RR. *Chem. Eur. J* 2004;10:875–887. j) Thayer DA, Yu HN, Galan MC, Wong C-H. *Angew. Chem. Int. Ed* 2005;44:4596–4599. k) Yang Y-Y, Ficht S, Brik A, Wong C-H. *J. Am. Chem. Soc* 2007;129:7690–7701. [PubMed: 17523644] l) Ficht S, Payne RJ, Brik A, Wong C-H. *Angew. Chem. Int. Ed* 2007;46:5975–5979. m) Ichikawa Y, Matsukawa Y, Isobe M. *J. Am. Chem. Soc* 2006;128:3934–3938. [PubMed: 16551100] n) Ladmiral V, Mantovani G, Clarkson GJ, Cauet S, Irwin JL, Haddleton DM. *J. Am. Chem. Soc* 2006;128:4823–4830. [PubMed: 16594719] o) Hotha S, Kashyap S. *J. Org. Chem*


- 2006;71:364–367. [PubMed: 16388660] p) Ichikawa Y, Ohara F, Kotsuki H, Nakano K. *Org. Lett* 2006;8:5009–5012. [PubMed: 17048830] q) Wittrock S, Becker T, Kunz H. *Angew. Chem. Int. Ed* 2007;46:5226–5230. r) Ni J, Song H, Wang Y, Stamos NM, Wang L-X. *Bioconjugate Chem* 2006;17:493–500. s) Kolomiets E, Johansson EMV, Renaudet O, Darbre T, Reymond J-L. *Org. Lett* 2007;8:14656–11468. t) Samantaray S, Marathe U, Dasgupta S, Nandicoori VK, Roy RP. *J. Am. Chem. Soc* 2008;130:2132–2133. [PubMed: 18229923]
6. a) Macindoe WM, van Oijen AH, Boons G-J. *Chem. Commun* 1998:847–848. b) Gamblin DP, Garnier SJ, Ward NJ, Oldham AJ, Fairbanks AJ, Davis BG. *Org. Biomol. Chem* 2003;1:3642–3644. [PubMed: 14649893] c) Gamblin DP, Garnier P, van Kasteren S, Oldham NJ, Fairbanks AJ, Davis BG. *Angew. Chem. Int. Ed* 2004;43:828–833. d) van Kasteren SI, Kramer HB, Jensen HH, Campbell SJ, Kirkpatrick J, Oldham NJ, Anthony DC, Davis BG. *Nature* 2007;446:1105–1109. [PubMed: 17460675] e) Bernardes GJL, Chalker JM, Errey JC, Davis BG. *J. Am. Chem. Soc* 2008;130:5052–5053. [PubMed: 18357986]
7. Bernardes GJL, Grayson EJ, Thompson S, Chalker JM, Errey JC, El Oualid F, Claridge TDW, Davis BG. *Angew. Chem. Int. Ed* 2008;47:2244–2247.
8. a) Garmaise, DI; Uchiyama, A.; McKay, AF. *J. Org. Chem* 1962;27:4509–4512. b) Ferrier RJ, Vethaviasar N. *J. Chem. Soc., Chem. Commun* 1970:1385–1387. c) Hackler RE, Balko TW. *J. Org. Chem* 1973;38:2106–2110. [PubMed: 4710101] d) Nakai T, Ari-Izumi A. *Tetrahedron Lett* 1976;17:2335–2338. e) Harano K, Ohizumi N, Hisano T. *Tetrahedron Lett* 1985;26:4203–4206. f) Harano K, Taguchi T. *Chem. Pharm. Bull* 1975;23:467–472. g) Nakai T, Mimura T, Ari-Izumi A. *Tetrahedron Lett* 1977:2425–2428. h) Ueno Y, Sano H, Okawara M. *Tetrahedron Lett* 1980;21:1767–1770. i) Eto M, Tajiri O, Nakagawa H, Harano K. *Tetrahedron* 1998;54:8009–8014. j) Overman LE, Roberts SW, Sneddon HF. *Org. Lett* 2008;8:1485–1488. [PubMed: 18336036]
9. Schmidt, RR. *Preparative Carbohydrate Chemistry*. Hanessian, S., editor. New York: Dekker; 1997. p. 283-312. Schmidt, RR.; Jung, K-H. *Carbohydrates in Chemistry and Biology*. Ernst, B.; Hart, GW.; Sinaÿ, P., editors. Vol. Vol. 1. Weinheim: Wiley-VCH; 2000. p. 5-59.
10. The glycosylation reaction was accompanied by partial cleavage of the O-2 acetate, which was detrimental to the yield of the product. Therefore, an acetylation step was included in the work-up protocol to reinstall any missing acetates.
11. a) Danehy JP, Elia VJ. *J. Org. Chem* 1972;37:369–373. b) Happer DAR, Mitchell JW, Wright GJ. *Aust. J. Chem* 1973;26:121–134. c) Ichimura A, Nosco DL, Deutsch E. *J. Am. Chem. Soc* 1983;105:844–850.
12. Volante RP. *Tetrahedron Lett* 1981;22:3119–3122.
13. Rodriguez EB, Scally GD, Stick RV. *Aust. J. Chem* 1990;43:1391–1405.
14. Sodeoka M, Yamada H, Shibasaki M. *J. Am. Chem. Soc* 1990;112:4906–4911.
15. When TLC indicated orthoester formation TMSOTf (0.1 eq) was added before the reaction was quenched.
16. Zibuck R, Streiber JM. *J. Org. Chem* 1989;54:4717–4719.
17. This compound showed a tendency to undergo allylic rearrangement during silica gel chromatography when moisture was not fully excluded.1c
18. Wen S, Guo Z. *Org. Lett* 2001;3:3773–3776. [PubMed: 11700135]





Scheme 1.
Ligation via the Desulfurative Allylic Disulfide Rearrangement




Scheme 2.
First Generation Approach to Precursor Synthesis






Scheme 3.
First Generation Approach Applied to a Sialic Acid Derivative




Scheme 4.
Second Generation Approach




Scheme 5.
Third Generation Approach



Scheme 6.
Preparation of Unprotected Neoglycosyl Donors





Scheme 7.
Preparation of an Alternative Linker




Scheme 8.
Preparation of Amide-Based Neoglycosyl Donors

Table 1
Neoglycoconjugate Formation with Protected Donors.

Neoglycosyl Donor



Neoglycosyl Donor

**5c**

5a

HS

BocHN

Neoglycosyl Donor

5b

5a







Table 2
Protecting Group-Free Neoglycoconjugate Preparation in Phosphate Buffer

Neoglycosyl Donor	Peptide
 <p>25b</p>	22
 <p>25c</p>	22

Neoglycosyl Donor

Peptide






22



26

Table 3

Amide-Based Neoglycopeptide Synthesis

Neoglycosyl Donor	Pept
 <p data-bbox="527 829 665 903">36a</p>	 <p data-bbox="1583 436 1615 462">22</p>
 <p data-bbox="706 1045 755 1071">36b</p>	22
 <p data-bbox="706 1339 755 1365">36b</p>	 <p data-bbox="1583 1354 1615 1375">39</p>